Published: eClinicalMedicine (The Lancet), May 2026
Researchers: Neuroscience Research Australia — 40 adults, randomized double-blind placebo-controlled crossover trial
1. What Was Studied?
Chronic neuropathic pain after spinal cord injury is one of the most difficult pain conditions to treat. It affects a significant proportion of people with spinal cord injuries and often responds poorly to conventional medications like gabapentin or antidepressants.
This trial tested high-dose CBD against placebo in 40 adults living with chronic neuropathic pain from spinal cord injury. Participants went through two six-week treatment periods — one on CBD, one on placebo — separated by a four-week break. The CBD dose was gradually increased over two weeks, starting at 200mg per day and reaching up to 800mg per day. Each participant served as their own comparison, which strengthens the data.
2. What Did They Find?
Pain intensity was significantly lower during the CBD treatment period compared to placebo — averaging 3.82 on a 10-point scale with CBD versus 4.36 with placebo
Nearly 38% of participants achieved at least a 30% reduction in pain on CBD, compared with 11% during the placebo period
Researchers described the effect as statistically significant but modest in magnitude
CBD was generally well tolerated at high doses — most side effects were mild, including tiredness, nausea and mild gastrointestinal effects
No serious adverse events were reported
3. What This Means
A 14% average reduction in pain might sound modest on paper — but for people living with chronic neuropathic pain that hasn't responded to other treatments, even a modest reduction can meaningfully change quality of life. The near-tripling of the proportion achieving 30% pain relief (38% vs 11%) is also a meaningful clinical finding.
This is the first trial to formally demonstrate that high-dose CBD can reduce self-reported neuropathic pain intensity in a placebo-controlled setting specifically for spinal cord injury patients. The researchers noted the findings are relevant to neuropathic pain broadly, not only to spinal cord injury.
4. What This Does NOT Mean
The effect was modest — CBD did not eliminate pain or produce dramatic relief for most participants
800mg per day is an exceptionally high dose, far above what most consumer products contain
This was a relatively small trial — 40 participants — and larger studies are needed
CBD at these doses may interact with other medications, particularly those metabolised by the liver
Consumer CBD products are not equivalent to the pharmaceutical-grade CBD used in this trial
5. Bottom Line
The first high-dose CBD trial for spinal cord injury pain found a statistically significant reduction in neuropathic pain intensity — modest but real, with nearly triple the proportion achieving meaningful relief compared to placebo.
